Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Archives of Internal Medicine
|
September 17, 2002
Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing
Allen Brinker, Judy Staffa
JAMA Internal Medicine
|
May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program
Doris Auth, Judy Staffa, Cynthia LaCivita
Pharmacoepidemiology and Drug Safety
|
January 5, 2008
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis
Mara McAdams, Judy Staffa, Gerald Dal Pan
Pharmacoepidemiology and Drug Safety
|
September 18, 2018
Commentary on "Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base"
Judy Staffa, Tamra Meyer, Alex Secora, et al.
JAMA Pediatrics
|
September 10, 2016
Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting
Jing Xu, Rajdeep Gill, Marisa Cruz, et al.
Pain
|
October 6, 2020
Patterns of opioid analgesic use in the U.S., 2009 to 2018
Corinne Woods, Grace Chai, Tamra Meyer, et al.
Pediatrics
|
June 20, 2012
Trends of outpatient prescription drug utilization in US children, 2002-2010
Grace Chai, Laura Governale, Ann W McMahon, et al.
Pharmacoepidemiology and Drug Safety
|
January 8, 2014
Drug risk assessment and data reuse
Solomon Iyasu, Judy Staffa, Dave Graham, et al.
Pharmacoepidemiology and Drug Safety
|
January 1, 2009
Emergency department visits attributed to selected analgesics, United States, 2004-2005
Mary Willy, Judith P Kelly, Parivash Nourjah, et al.
Pharmacoepidemiology and Drug Safety
|
December 16, 2017
Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review
David Tyler Coyle, Chih-Ying Pratt, Josephine Ocran-Appiah, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Archives of Internal Medicine
|
September 17, 2002
Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing
Allen Brinker, Judy Staffa
JAMA Internal Medicine
|
May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program
Doris Auth, Judy Staffa, Cynthia LaCivita
Pharmacoepidemiology and Drug Safety
|
January 5, 2008
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis
Mara McAdams, Judy Staffa, Gerald Dal Pan
Pharmacoepidemiology and Drug Safety
|
September 18, 2018
Commentary on "Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base"
Judy Staffa, Tamra Meyer, Alex Secora, et al.
JAMA Pediatrics
|
September 10, 2016
Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting
Jing Xu, Rajdeep Gill, Marisa Cruz, et al.
Pain
|
October 6, 2020
Patterns of opioid analgesic use in the U.S., 2009 to 2018
Corinne Woods, Grace Chai, Tamra Meyer, et al.
Pediatrics
|
June 20, 2012
Trends of outpatient prescription drug utilization in US children, 2002-2010
Grace Chai, Laura Governale, Ann W McMahon, et al.
Pharmacoepidemiology and Drug Safety
|
January 8, 2014
Drug risk assessment and data reuse
Solomon Iyasu, Judy Staffa, Dave Graham, et al.
Pharmacoepidemiology and Drug Safety
|
January 1, 2009
Emergency department visits attributed to selected analgesics, United States, 2004-2005
Mary Willy, Judith P Kelly, Parivash Nourjah, et al.
Pharmacoepidemiology and Drug Safety
|
December 16, 2017
Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review
David Tyler Coyle, Chih-Ying Pratt, Josephine Ocran-Appiah, et al.
Page
of 2